Body composition and adipokines changes after initial treatment with darunavir-ritonavir plus either raltegravir or tenofovir disoproxil fumarate-emtricitabine: A substudy of the NEAT001/ANRS143 randomised trial
| Autor: | Bernardino, Jose I., Mocroft, Amanda, Wallet, Cedrick, de Wit, Stéphane, Katlama, Christine, Reiss, Peter, Mallon, Patrick W., Richert, Laura, Molina, Jean-Michel, Knobel Freud, Hernando, Morlat, Philippe, Babiker, Abdel, Pozniac, Anton, Raffi, Francois, Arribas, José Ramón, NEAT001/ANRS143 Trial Study Group |
|---|---|
| Přispěvatelé: | UAM. Departamento de Medicina, Department of Internal Medicine [Madrid, Spain], Hospital Universitario La Paz [Madrid, Spain]-IdiPAZ - Instituto de Investigación La Paz [Madrid, Spain], University College of London [London] (UCL), Bordeaux population health (BPH), Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université libre de Bruxelles (ULB), CHU Saint-Pierre, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Sorbonne Université (SU), Sorbonne Université - Faculté de Médecine (SU FM), University of Amsterdam [Amsterdam] (UvA), Academic Medical Center - Academisch Medisch Centrum [Amsterdam] (AMC), University College Dublin [Dublin] (UCD), Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Génétique et Ecologie des Virus, Génétique des Virus et Pathogénèse des Maladies Virales, Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), IMIM-Hospital del Mar, Generalitat de Catalunya, Service de médecine interne et maladies infectieuses [Bordeaux], CHU Bordeaux [Bordeaux]-Groupe hospitalier Saint-André, Medical Research Council Clinical Trials Unit (MRC CTU), Chelsea and Westminster Hospital, Service des maladies infectieuses et tropicales [CHU Nantes], Centre hospitalier universitaire de Nantes (CHU Nantes), NEAT is a project funded to the Instituto Superiori di Sanita-Rome, by the European Union under the Sixth Framework Programme, project number LSHP-CT-2006-037570. This analysis was also partially funded by a grant from the Ministerio de Sanidad y Asuntos Sociales de España (2009/TRA-054). The trial was also supported by Gilead Sciences, Janssen Pharmaceuticals, and Merck Laboratories, and the French National Institute for Health and Medical Research-France Recherche Nord & Sud SIDA-HIV Hépatites (Inserm-ANRS) is the sponsor and a funder of the trial., Gestionnaire, Hal Sorbonne Université, Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Global Health, APH - Aging & Later Life |
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
Leptin
0301 basic medicine Male Time Factors Lipodystrophy Physiology Peptide Hormones [SDV]Life Sciences [q-bio] Psychologie appliquée Pathology and Laboratory Medicine Biochemistry Body Mass Index Fats 0302 clinical medicine Bone Density Immune Physiology Medicine and Health Sciences 030212 general & internal medicine Musculoskeletal System Immune Response Innate Immune System therapy HAART Multidisciplinary Emtricitabine Tenofovir Disoproxil Fumarate Drug Combination Sida -- Tractament Sciences bio-médicales et agricoles Lipids 3. Good health [SDV] Life Sciences [q-bio] Arms Adipose Tissue Connective Tissue Body Composition Cytokines Medicine Female Anatomy Biologie Research Article medicine.drug Adult medicine.medical_specialty Medicina Science Immunology Urology Adipokine Emtricitabine 03 medical and health sciences Signs and Symptoms Adipokines Diagnostic Medicine Raltegravir Potassium medicine Humans Bone Darunavir Cos humà -- Composició Inflammation business.industry Biology and Life Sciences HIV Molecular Development Raltegravir 030112 virology Hormones Fibroblast Growth Factor-23 Biological Tissue Body Limbs Immune System Lean body mass Ritonavir business Body mass index Developmental Biology |
| Zdroj: | Dipòsit Digital de Documents de la UAB Universitat Autònoma de Barcelona PLoS ONE PLoS ONE, Public Library of Science, 2019, 14 (1), pp.e0209911. ⟨10.1371/journal.pone.0209911⟩ PLoS ONE, 14(1):e0209911. Public Library of Science Biblos-e Archivo. Repositorio Institucional de la UAM instname PLoS ONE, Vol 14, Iss 1, p e0209911 (2019) PloS one, 14 (1 |
| ISSN: | 1932-6203 |
| Popis: | Background Comparison of changes in body composition, adipokines and inflammatory markers after initial therapy with a nucleos(t)ide reverse transcriptase inhibitor (N(t)RTI)- sparing or containing regimen are scarce. Design Randomised Clinical Trial. Methods This is the body composition substudy of NEAT 001/ANRS 143, a randomised trial comparing darunavir/ritonavir (DRV/r) plus either raltegravir (RAL) or tenofovir disoproxil fumarate/ emtricitabine (TDF/FTC) in 805 ART naïve HIV-infected adults. The primary endpoint was percentage change in limb fat at week 96. Secondary endpoints were associations among these changes and metabolic markers (IL-6, insulin, leptin, adiponectin, FGF-23). Results 126 subjects (61 DRV/r + RAL and 65 DRV/r + TDF/FTC) were included. The rate of change in BMI between groups for RAL versus TDF/FTC at week 96 was 1.5% per 48-week period (p = 0.015). The rate of change in limb fat mass, trunk fat mass, total body fat and total lean mass was for RAL versus TDF/FTC at week 96 was 2.5% (p = 0.38), 7.3% ((p = 0.021), 4.9% (p = 0.061) and 1.3% (p = 0.12) respectively. Baseline insulin and leptin levels were correlated with baseline limb fat and trunk fat mass [r = 0.31 (p = 0.0043)/r = 0.28 (p = 0.0011) for limb fat, and r = 0.63 (p SCOPUS: ar.j info:eu-repo/semantics/published |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|